Skip to main content

Table 2 Event rates and odds ratios* for readmission and mortality within 365 days in patients with asthma (n = 1341) following an acute hospitalization, stratified by suPAR quartiles

From: The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma – a retrospective cohort study

Follow-up

Variable

Readmission

Mortality

Analysis

suPAR

Events (%)|

OR (95% CI)

P-value

Events (%)|

OR (95% CI)

P-value

30 days

Continuous

 

1.36 (1.0–1.8)

0.042

 

1.85 (0.8–4.4)

0.171

Adjusted

1st quartile

35 (12.4%)

1

 

1 (0.4%)

1

 
 

2nd quartile

36 (13.5%)

1.00 (0.7–1.7)

0.99

2 (0.8%)

N/A§

 

3rd quartile

40 (16.9%)

1.14 (0.7–1.9)

0.62

1 (0.4%)

0.34 (0.02–6.4)

0.47

4th quartile

78 (27.6%)

1.96 (1.1–3.3)

0.014

17 (6.0%)

0.95 (0.08–11.2)

0.97

Total

189 (41.8%)

  

21 (36.8%)

  

90 days

Continuous

 

1.26 (1.0–1.6)

0.08

 

2.79 (1.5–5.3)

0.0019

Adjusted

1st quartile

63 (22.3%)

1

 

1 (0.4%)

1

 
 

2nd quartile

61 (22.9%)

1.00 (0.7–1.5)

0.99

2 (0.8%)

N/A§

 

3rd quartile

61 (25.7%)

1.06 (0.7–1.6)

0.81

6 (2.5%)

1.63 (0.2–15.8)

0.67

4th quartile

104 (36.7%)

1.58 (1.0–2.5)

0.049

29 (10.2%)

2.39 (0.3–21.3)

0.44

Total

289 (63.9%)

  

38 (66.7%)

  

365 days

Continuous

 

1.27 (1.0–1.6)

0.052

 

2.94 (1.7–5.1)

0.0002

Adjusted

1st quartile

105 (37.2%)

1

 

2 (0.7%)

1

 

2nd quartile

107 (40.2%)

1.03 (0.7–1.5)

0.88

4 (1.5%)

0.19 (0.02–2.3)

0.19

3rd quartile

104 (43.9%)

1.26 (0.8–1.9)

0.25

9 (3.8%)

1.58 (0.3–8.6)

0.60

4th quartile

136 (48.1%)

1.56 (1.0–2.4)

0.044

42 (14.8%)

2.75 (0.5–13.9)

0.22

Total

452 (100%)

  

57 (100%)

  
  1. *Multivariable adjusted analyses included age, sex, Charlson comorbidity score, blood eosinophil count and CRP
  2. suPAR quartile cut-offs: Q1: < 1.9 ng/mL (n = 282), Q2: 1.9–2.6 ng/mL (n = 266), Q3: 2.61–3.5 ng/mL (n = 237), Q4: > 3.5 ng/mL (n = 283)
  3. Only patients with a minimum of 365 days follow-up included in analyses (n = 1068)
  4. §Calculation not possible due to too few events
  5. |Shown as number of patients with event (percentage out of total patient population in each group of blood eosinophil count (low, medium, high) at 365 days)
  6. Total number of events at follow-up as a percentage of number of events at 365 days
  7. CRP – C-Reactive Protein
  8. CI – Confidence Interval
  9. OR – Odds Ratio
  10. suPAR - Soluble Urokinase Plasminogen Activator Receptor